All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000440-24 | A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic Lym... | bad-data | |
| Reported results | 2004-002505-74 | A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy o... | 2005-12-06 | due-trials |
| Reported results | 2005-002258-23 | A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio ... | 2010-01-13 | due-trials |
| Reported results | 2005-005542-39 | An Open-Label Extended-Use Study of Oral CEP-701 in Patients With Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701 | 2009-11-11 | due-trials |
| Reported results | 2007-007555-14 | An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Dep... | 2009-03-02 | due-trials |
| Reported results | 2008-000709-12 | Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe... | 2016-02-22 | due-trials |
| Exempt, with results | 2008-001679-31 | A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | 2011-11-17 | not-yet-due |
| Reported results | 2008-001841-24 | A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | 2011-05-17 | due-trials |
| Reported results | 2009-013778-41 | "Estudio abierto para determinar la dosis máxima tolerada y evaluar la eficacia y seguridad de CEP-18770 en pacientes con mieloma múltiple recidivante y resistente al tratamiento más reciente" | 2012-11-15 | due-trials |
| Reported results Terminated | 2009-014544-11 | A 12-Month, open-label Study to evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/day) as Treatment for Patients with excessive Sleepiness associated with mild or moderte ... | 2010-10-28 | due-trials |
| Reported results | 2009-014545-83 | A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with ... | 2011-01-06 | due-trials |
| Reported results | 2009-016634-27 | A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depr... | 2012-11-21 | due-trials |
| Reported results | 2009-016648-38 | A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bip... | 2013-10-09 | due-trials |
| Reported results | 2009-016667-11 | A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depr... | 2012-03-16 | due-trials |
| Reported results | 2009-016725-34 | An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL) | 2011-10-03 | due-trials |
| Reported results | 2010-018383-16 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus | 2012-01-31 | due-trials |
| Reported results | 2010-019293-32 | An Open-Label Long-Term Study of the Safety and Tolerability of Repeated administration of CEP-33457 in Patients With Systemic Lupus Erythematosus | 2012-06-14 | due-trials |
| Reported results | 2010-023623-26 | A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression... | 2013-07-29 | due-trials |
| Reported results | 2010-024006-35 | A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye... | 2014-04-03 | due-trials |
| Reported results | 2010-024540-15 | An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ... | 2015-01-16 | due-trials |
| Exempt, with results Terminated | 2012-005510-20 | A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/day) in Children and Adolescents with... | not-yet-due |